Search results

558 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Social care guidelines Remove Social care guidelines filter

Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abicipar pegol for treating wet age-related macular degeneration ID1533

In development [GID-TA10511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

In development [GID-TA10442] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]

In development [GID-TA10629] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]

In development [GID-TA10690] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

In development [GID-TA10507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diabetes update

In development [GID-NG10152] Expected publication date: TBC

Type

NICE guideline

Status

In development
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]

In development [GID-TA10614] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]

In development [GID-TA10618] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Baloxavir marboxil for treating influenza [ID1537]

In development [GID-TA10559] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

In development [GID-TA10544] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

In development [GID-TA10615] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

In development [GID-TA10387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Midostaurin for treating advanced systemic mastocytosis ID1573

In development [GID-TA10503] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Postnatal care

In development [GID-NG10070] Expected publication date: 07 April 2021

Type

NICE guideline

Status

In development
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury

In development [GID-NG10181] Expected publication date: TBC

Type

NICE guideline

Status

In development
Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

In development [GID-TAG418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Type

Technology appraisal guidance

Status

In development
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous leg ulcers - new treatments [ID394]

In development [GID-TAG370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

In development [GID-TA10597] Expected publication date: 27 October 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]

In development [GID-TA10703] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]

In development [GID-TA10482] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]

In development [GID-TA10650] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

In development [GID-TA10612] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development